Navigation Links
$2.3 million in NIH funding for promising cancer research at Cincinnati Children's
Date:4/15/2010

CINCINNATI Two scientific teams at Cincinnati Children's Hospital Medical Center are receiving a total of $2.3 million in research funding from the National Institutes of Health (NIH) to continue promising studies seeking novel treatments for leukemia and bone marrow failure.

A team led by Yi Zheng, Ph.D., and James Mulloy, Ph.D., is getting a five-year grant totaling $1.04 million from NIH's National Cancer Institute entitled, "Targeting CDC42 in Leukemia Stem Cells." Qishen Pang, Ph.D., and colleagues are being awarded a five-year grant totaling $1.25 million from the National Heart, Lung and Blood Institute entitled, "Role of FA Protein Complexes in Hematopoiesis."

The scientists are all part of the Cancer and Blood Diseases Institute at Cincinnati Children's and its divisions of Experimental Hematology/Cancer Biology and Hematology/Oncology. Dr. Zheng is director of Experimental Hematology/Cancer Biology.

Research into CDC42 involves a protein that normally is crucial to cell adhesion, survival and migration. Scientists have learned that under certain conditions CDC42 stimulates development of disease initiating cells in bone marrow and leukemia stem cells, which they believe can fuel prolonged disease, relapse and mortality. The research team has been studying this process in Acute Myeloid Leukemia (AML), a complex blood cancer that often suffers from relapse after conventional chemotherapy treatment.

Ongoing studies of mice bred to model human leukemia including a novel mouse model of AML developed by Dr. Mulloy's laboratory and of human leukemia cells have shown blocking CDC42 inhibits formation of cells that initiate leukemia and promotes programmed cell death of leukemia cells. The goal of the newly funded research is to develop a new therapeutic strategy for targeting CDC42 to eliminate leukemia stem cells in bone marrow for leukemias that are resistant to conventional chemotherapies.

Dr. Pang's team is studying molecular mechanics of how Fanconi anemia (FA) proteins regulate cell response to oxidative stress during hematopoiesis, the process of blood cell formation in bone marrow. This is important to understanding the progression Fanconi anemia, bone marrow failure, myelodisplastic syndrome (once called pre-leukemia), AML and the underlying genomic instability in people with Fanconi anemia.

The researchers have already shown that bone marrow cells from patients with Fanconi anemia accumulate high levels of molecules called reactive oxygen species (ROS). ROS molecules are the source of oxidative stress and bone marrow cells in people with Fanconi anemia are sensitive to ROS suppressing the formation of blood stem and progenitor cells. The scientists have also demonstrated that abnormal accumulation of ROS leads to formation of leukemic cells in a mouse model of Fanconi anemia. The team has reported that a specific FA protein, FANCD2, binds and works with the transcription factor FOXO3a, which helps control the transfer of genetic information in cellular stress response processes. Together hey form a complex that helps provide a cellular defense system against oxidative stress.

By using cells from children with Fanconi anemia and working with mouse models in their continued research, the scientists hope to find new therapeutic targets to treat or prevent bone marrow failure and related cancer progression.


'/>"/>

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Related biology news :

1. Structure of 450 million year old protein reveals evolutions steps
2. First orchid fossil puts showy blooms at some 80 million years old
3. SyntheMed Completes $2.8 Million Equity Financing
4. Rutgers Genetics receives $7.8 million for autism research
5. Seattle Childrens Hospital leads $23.7 million NIH grant to study gene repair
6. UD leads $5.3-million research project on rice epigenetics
7. Rutgers high school outreach gets $3 million boost from NSF
8. NIH awards researcher $1.5 million new innovator grant for fruit-fly studies of prion proteins
9. UD leads $5.3-million research project on rice epigenetics
10. $22 million gift from Alfred Taubman launches new biomedical research institute
11. Nanobiosym awarded $2 million DTRA contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
Breaking Biology News(10 mins):
(Date:5/23/2017)... ... May 22, 2017 , ... NetDimensions has been ranked ... Research Globe™ for Corporate Learning, 2017. , Aragon Research defines Leaders as organizations ... effectively perform against those strategies. NetDimensions’ ranking as a Leader due to its ...
(Date:5/23/2017)... ... May 23, 2017 , ... Kathy Goin is joining ... Operations. She brings years of expertise in establishing and leading clinical operations at ... a licensed occupational therapist, through a variety of leadership roles in Clinical Operations, ...
(Date:5/22/2017)... ... ... Stratevi, a boutique firm that partners with healthcare companies to creatively develop and ... downtown Boston at 745 Atlantic Ave. , “We are seeing that even the ... value they provide, not just to patients, but also payers. Having a presence in ...
(Date:5/21/2017)... (PRWEB) , ... May 20, 2017 , ... ... that helps avoid the lengthy trial and error process by finding the right ... It can also strengthen the doctor-patient relationship through a personalized approach to treatment. ...
Breaking Biology Technology: